Kevin Bruce Johnson - 27 Jan 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Chief Regulatory Officer
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
27 Jan 2025
Net transactions value
$0
Form type
4
Filing time
29 Jan 2025, 16:22:59 UTC
Previous filing
23 Oct 2023
Next filing
17 Oct 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Employee Stock Option (Right to Buy) Award $0 +58,000 $0.000000 58,000 27 Jan 2025 Common Stock 58,000 $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as to 25% of the shares on January 27, 2026, with the remainder vesting in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.